Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bradley A. Hauser
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 10
- Beta
- -1.30
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -34.93
Financials
Net Income
$-2.73MEBITDA
$-2.73MFree Cash Flow
$-3.54MEPS (diluted)
$-5.02Shares Outstanding (diluted)
543.7K-42.3%Operating Expenses
$2.77MCash & Debt
$3.46MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-16.71M | $-48.64 |
| 2025 | $0.00 | $-11.41M | $-135.65 |
| 2024 | $0.00 | $-15.43M | $-343.78 |
| 2023 | $0.00 | $-1.99M | $-44.48 |
| 2022 | $0.00 | $-13.33M | $-286.98 |
Valuation
AMIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·7h ago·Neutral
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain
View source ↗
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-6.20 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-5.02 vs $-6.40beat
- Thu, Jun 4$-4.83 vs $-4.83beat
- Thu, Feb 12$-7.56 vs $-7.56beat
- Fri, Nov 14$-28.98 vs $-31.50beat
- Wed, Aug 13$-22.47 vs $-18.59miss
- Thu, May 29$-38.53 vs $-25.93miss
Estimates and results for AMIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMIX officers and directors.
- Bought
- $1k
- Sold
- —
2 trades
0 trades
- Robins David Andrewbought
- Biostar Ventures Iii, L.p.bought
27 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.